Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review

Esperite NV (ESP) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH138666FSA
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Esperite NV (ESP)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.

- Corporate strategy - Analyst's summarization of the company's business strategy.

- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history - Progression of key events associated with the company.

- Major products and services - A list of major products, services and brands of the company.

- Key competitors - A list of key competitors to the company.

- Key employees - A list of the key executives of the company.

- Executive biographies - A brief summary of the executives' employment history.

- Key operational heads - A list of personnel heading key departments/functions.

- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities - A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Esperite NV (Esperite) is a regenerative and precision medicine company. It collects, processes and stores human adult stem cells obtained from umbilical cord blood and cord tissue. Esperite offers a diagnostic system built on the Next Generation Sequencing technology (NGS) that enables laboratories for performing with bioinformatics-based genetic analysis. The company operates a research and development division, the Cell Factory, which is involved in developing advanced cell therapy medicinal products and new therapies in the field of regenerative medicine. The company works in partnership with pharmaceutical and biotechnology companies to advance the development of its products and services. Esperite is headquartred in Amsterdam, the Netherlands.

Esperite NV Key Recent Developments

Nov 23,2018: ESPERITE : financial results for 2017 are published

Nov 06,2018: Esperite Group with The Cell Factory expands its Extracellular Vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia.

Sep 13,2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva

Jun 19,2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies

Jun 11,2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Esperite NV-Key Facts 6

Esperite NV-Key Employees 7

Esperite NV-Key Employee Biographies 8

Esperite NV-Major Products and Services 9

Esperite NV-History 10

Esperite NV-Company Statement 13

Esperite NV-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 - Company Analysis 17

Company Overview 17

Esperite NV-Business Description 18

Business Segment: Genoma 18

Overview 18

Performance 18

Business Segment: Holding 18

Overview 18

Performance 18

Business Segment: Other 18

Overview 18

Performance 18

Business Segment: Stem Cell 18

Overview 18

Performance 19

Business Segment: The Cell Factory 19

Overview 19

Performance 19

Esperite NV-SWOT Analysis 20

SWOT Analysis-Overview 20

Esperite NV-Strengths 20

Esperite NV-Weaknesses 21

Esperite NV-Opportunities 22

Esperite NV-Threats 23

Esperite NV-Key Competitors 24

Section 3 - Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4 - Company's Lifesciences Financial Deals and Alliances 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Esperite NV, Recent Deals Summary 33

Section 5 - Company's Recent Developments 34

Nov 23, 2018: ESPERITE : financial results for 2017 are published 34

Sep 13, 2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva 41

Jun 19, 2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies 42

Jun 11, 2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding 43

Mar 29, 2018: Esperite, The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV's drugs for treatment of inflammatory diseases 44

Jan 10, 2018: ESPERITE transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs 46

Oct 09, 2017: Esperite with CryoSave enters the Ukrainian market and fosters its leadership position in Europe 47

Oct 02, 2017: ESPERITE publishes its half-year report 48

May 31, 2017: ESPERITE Q1 consolidated revenue higher compared to budget 49

May 23, 2017: Esperite Financial Results For 2016 Published 50

Section 6 - Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Esperite NV, Performance Chart (2013-2017) 28

Esperite NV, Ratio Charts 30

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

List of Tables

Esperite NV, Key Facts 6

Esperite NV, Key Employees 7

Esperite NV, Key Employee Biographies 8

Esperite NV, Major Products and Services 9

Esperite NV, History 10

Esperite NV, Subsidiaries 15

Esperite NV, Key Competitors 24

Esperite NV, Ratios based on current share price 25

Esperite NV, Annual Ratios 26

Esperite NV, Annual Ratios (Cont...1) 27

Esperite NV, Interim Ratios 29

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Esperite NV, Recent Deals Summary 33

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Virgin Health Bank

NHS Cord Blood Bank

New England Cord Blood Bank, Inc

Cryopraxis Criobiologia Ltda

Cells4Life Group LLP

Esperite NV, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8920
Site License
USD 250 INR 17840
Corporate User License
USD 375 INR 26760

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com